The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.
Money Talk With Tiff on MSN19h
Monarch Money Review: A Comprehensive Look at this Budgeting App
Monarch is currently running a promo!Get 50% OFF your first year with code NEWYEAR2025 Monarch Money is a budgeting app ...
Institute of Food Technologists3h
Charting Feelings About Food
Researcher Laura Coelho of the University of Guelph has created a new sensory science methodology called EmoMap.
Top UK Dividend Stocks To Consider In March 2025
As the UK's FTSE 100 index experiences volatility due to weak trade data from China, investors are closely watching how global economic trends impact the market. In such uncertain times, dividend ...
Guard Therapeutics International AB: Two-thirds of patients enrolled in Guard Therapeutics' Phase 2b POINTER study
Guard Therapeutics announced today that it has reached another key milestone in its ongoing clinical development program. Two-thirds of the approximately 160 planned patients have now been enrolled in ...